Abstract
Many COVID-19 patients develop a coagulopathy characterized by thrombocytopenia, minor prolongation of bleeding times and elevated serum d-dimer and fibrinogen levels, similar to consumption coagulopathy [1], together with severe endothelial injury, and alveolar capillary microthrombi [2]. Moreover, several studies reported an increased risk of venous thromboembolism (VTE), disseminated intravascular coagulation (DIC), as well as large-vessel thrombosis. In particular, the incidence of VTE in COVID-19 patients was 8 to 69% [3], which is significantly higher than in critically ill patients with H1N1 influenza and sepsis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
